370 related articles for article (PubMed ID: 28473471)
1. Are targeted therapies for diabetic cardiomyopathy on the horizon?
Tate M; Grieve DJ; Ritchie RH
Clin Sci (Lond); 2017 May; 131(10):897-915. PubMed ID: 28473471
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes.
Prakoso D; De Blasio MJ; Tate M; Kiriazis H; Donner DG; Qian H; Nash D; Deo M; Weeks KL; Parry LJ; Gregorevic P; McMullen JR; Ritchie RH
Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H840-H852. PubMed ID: 32142359
[TBL] [Abstract][Full Text] [Related]
3. Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes.
Stanton AM; Vaduganathan M; Chang LS; Turchin A; Januzzi JL; Aroda VR
Curr Diab Rep; 2021 Sep; 21(10):41. PubMed ID: 34580767
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.
Jia G; DeMarco VG; Sowers JR
Nat Rev Endocrinol; 2016 Mar; 12(3):144-53. PubMed ID: 26678809
[TBL] [Abstract][Full Text] [Related]
5. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.
Seferović PM; Paulus WJ
Eur Heart J; 2015 Jul; 36(27):1718-27, 1727a-1727c. PubMed ID: 25888006
[TBL] [Abstract][Full Text] [Related]
6. Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat.
Tate M; Deo M; Cao AH; Hood SG; Huynh K; Kiriazis H; Du XJ; Julius TL; Figtree GA; Dusting GJ; Kaye DM; Ritchie RH
Diab Vasc Dis Res; 2017 Sep; 14(5):423-433. PubMed ID: 28565941
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.
Jia G; Hill MA; Sowers JR
Circ Res; 2018 Feb; 122(4):624-638. PubMed ID: 29449364
[TBL] [Abstract][Full Text] [Related]
8. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.
Wang L; Cai Y; Jian L; Cheung CW; Zhang L; Xia Z
Cardiovasc Diabetol; 2021 Jan; 20(1):2. PubMed ID: 33397369
[TBL] [Abstract][Full Text] [Related]
9. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes.
Mandavia CH; Aroor AR; Demarco VG; Sowers JR
Life Sci; 2013 Mar; 92(11):601-8. PubMed ID: 23147391
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.
Prakoso D; De Blasio MJ; Qin C; Rosli S; Kiriazis H; Qian H; Du XJ; Weeks KL; Gregorevic P; McMullen JR; Ritchie RH
Clin Sci (Lond); 2017 Jun; 131(12):1345-1360. PubMed ID: 28487469
[TBL] [Abstract][Full Text] [Related]
11. [Diabetic cardiomyopathy].
Huang YQ; Wang X; Kong W
Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):31-6. PubMed ID: 21417012
[TBL] [Abstract][Full Text] [Related]
12. Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy.
Masuda T; Muto S; Fujisawa G; Iwazu Y; Kimura M; Kobayashi T; Nonaka-Sarukawa M; Sasaki N; Watanabe Y; Shinohara M; Murakami T; Shimada K; Kobayashi E; Kusano E
Am J Physiol Heart Circ Physiol; 2012 May; 302(9):H1871-83. PubMed ID: 22389386
[TBL] [Abstract][Full Text] [Related]
13. The role of hyperglycaemia in the development of diabetic cardiomyopathy.
El Hayek MS; Ernande L; Benitah JP; Gomez AM; Pereira L
Arch Cardiovasc Dis; 2021 Nov; 114(11):748-760. PubMed ID: 34627704
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy.
Alonso N; Moliner P; Mauricio D
Adv Exp Med Biol; 2018; 1067():197-217. PubMed ID: 28980272
[TBL] [Abstract][Full Text] [Related]
15. Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy.
Parim B; Sathibabu Uddandrao VV; Saravanan G
Heart Fail Rev; 2019 Mar; 24(2):279-299. PubMed ID: 30349977
[TBL] [Abstract][Full Text] [Related]
16. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.
Ritchie RH; Zerenturk EJ; Prakoso D; Calkin AC
J Mol Endocrinol; 2017 May; 58(4):R225-R240. PubMed ID: 28373293
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of the nitroxyl donor 1-nitrosocyclo hexyl acetate limits left ventricular diastolic dysfunction in a mouse model of diabetes mellitus in vivo.
Cao N; Wong YG; Rosli S; Kiriazis H; Huynh K; Qin C; Du XJ; Kemp-Harper BK; Ritchie RH
Circ Heart Fail; 2015 May; 8(3):572-81. PubMed ID: 25737497
[TBL] [Abstract][Full Text] [Related]
18. Role of AMP-activated protein kinase on cardio-metabolic abnormalities in the development of diabetic cardiomyopathy: A molecular landscape.
Haye A; Ansari MA; Rahman SO; Shamsi Y; Ahmed D; Sharma M
Eur J Pharmacol; 2020 Dec; 888():173376. PubMed ID: 32810493
[TBL] [Abstract][Full Text] [Related]
19. Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?
Palomer X; Pizarro-Delgado J; Vázquez-Carrera M
Trends Pharmacol Sci; 2018 May; 39(5):452-467. PubMed ID: 29605388
[TBL] [Abstract][Full Text] [Related]
20. Morphological characteristics in diabetic cardiomyopathy associated with autophagy.
Kanamori H; Naruse G; Yoshida A; Minatoguchi S; Watanabe T; Kawaguchi T; Tanaka T; Yamada Y; Takasugi H; Mikami A; Minatoguchi S; Miyazaki T; Okura H
J Cardiol; 2021 Jan; 77(1):30-40. PubMed ID: 32907780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
